PRONOUNCE was the first global randomized trial with blinded adjudication of CV outcomes, in patients with PCa and recorded no difference in MACE risk in patients with known CVD, between degarelix (GnRH antagonist) and leuprolide (GnRHa). Here, GNRH1 is linked to posterior cortical atrophy.